
Kardigan is a heart health company working to make cardiovascular disease preventable, curable and no longer the leading cause of death in the world.
It is Kardigan’s mission to develop multiple targeted treatments in parallel that bring people with cardiovascular diseases to the cures they deserve.
Led by Tassos Gianakakos, Jay Edelberg, M.D., Ph.D., and Bob McDowell, Ph.D., Kardigan’s co-founders have reunited after leading MyoKardia to discover and develop mavacamten, the first cardiac myosin inhibitor, resulting in an acquisition by Bristol Myers Squibb in 2020.
We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team that is driven to improve the lives of patients.
At Kardigan, we are motivated by our values which guide how we work, interact, and achieve our goals. Driven by patients and their families, we are deeply committed to improving the lives of patients and prioritizing their needs above all else. We believe in being authentic—leading with truth to bring out the best in others by creating an environment where every person knows they will be fully accepted. With an eagerness to learn, we encourage the highest levels of curiosity and are open to changing our minds. We are committed to winning as a team with urgency, excellence, and intention, and support each other no matter what role we play or where we sit. Lastly, we strive to enable the impossible because patients are counting on us. We are not afraid to take risks to unlock innovation and advance scientific discoveries.
These values are the foundation of our work, empowering us to make a real difference, every day.
Kardigan's Clinical Data Analytics team is a collaborative and technical partner in advancing our portfolio of investigational cardiovascular therapies. The team is composed of two closely aligned groups, Statistical Programming and Data Science, that turn clinical trial data into submission-ready outputs and actionable insights. Working closely with colleagues across Biostatistics, Clinical Development, and Data Management, the team produces analysis datasets, statistical outputs, dashboards, and exploratory analyses that support high-quality decisions throughout development.
We are building a team that combines technical excellence with a forward-looking, innovation-driven mindset. Team members have the opportunity to modernize how clinical data is programmed, analyzed, and explored, applying tools like automation and AI to strengthen our work. This helps us move with speed and precision while maintaining the highest standards of quality, ethics, and compliance, supporting our mission to bring transformative treatments to people living with cardiovascular disease.
Kardigan is seeking an experienced and forward-looking leader to serve as Head of Statistical Programming. This individual will be accountable for the strategy, organization, quality, and timely delivery of statistical programming across Kardigan’s clinical portfolio. The role will lead and develop the internal programming team, oversee CRO and contractor partnerships, establish scalable programming standards and quality processes, and provide functional leadership for regulatory submissions and health-authority interactions. The Head of Statistical Programming will also shape Kardigan’s programming technology and operating-model roadmap, including the effective use of SAS, R, automation, reusable tools, and a validated statistical computing environment. The successful candidate will combine strong technical expertise with portfolio leadership, operational discipline, vendor-management experience, and the ability to collaborate effectively across Biostatistics, Clinical Data Management, Clinical Development, Regulatory, Quality, and IT.
Exact Compensation may vary based on skills, experience and location.
Pay range
$248,000—$323,000 USD

Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures. By matching critical disease drivers with treatment responders identified in clinical trials, Kardigan is developing a portfolio of medicines that modify the underlying cardiovascular disease pathophysiology to get patients closer to the cures they deserve. Kardigan has significant East and West Coast operations and focus.
For more information about Kardigan, please visit kardigan.bio. If you are interested in joining our passionate and driven team with deep cardiovascular, biotechnology and operational expertise, please visit kardigan.bio or the careers tab of this page.